天津中医药2017，Vol.34Issue(3)：163-164,2.DOI:10.11656/j.issn.1672-1519.2017.03.05
黄葵胶囊联合缬沙坦治疗早期糖尿病肾病的临床疗效及安全性观察
Observation on clinical effect and safety on early diabetic nephropathy treated with ambrette capsule combined valsartan
摘要
Abstract
[Objective] To observe the clinical curative effect and safety of ambrette capsules combined valsartan capsules in treating ear-ly diabetic nephropathy patients. [Methods] Eighty patients with early diabetic nephropathy were selected and randomly divided into ob-servation group and control group, 40 cases in each group. Two groups of patients were given the conventional foundation treatment. The observation group of patients were given oral ambrette capsules combined valsartan capsules treatment. Patients in control group were given valsartan capsules treatment. All groups were given drug treatment for 3 months continuously. The level of urine trace albumin ex-cretion rate (UAER), serum urea nitrogen (BUN) and creatinine (Scr) changes between two groups of patients before and after treat-ment would be compared and analyzed. [Results] Compared among the UAER, BUN and Scr of observation group before and after treat-ment,the difference was statistically significant. Compared among the UAER, BUN, Scr of control group before and after treatment,the difference was statistically significant. The UAER of observation group is decreased more significantly than the control group (P<0.05) after treatment. The degree of decrease in BUN and Scr between two groups after treatment is not obvious (P>0.05). [Conclusion] Using ambrette capsules combined valsartan capsules treating early diabetic nephropathy, both had good synergetic effect.关键词
黄葵胶囊/缬沙坦胶囊/早期糖尿病肾病Key words
ambrette capsule/valsartan capsule/early diabetic nephropathy分类
医药卫生引用本文复制引用
戴璇,袁连方,李月红..黄葵胶囊联合缬沙坦治疗早期糖尿病肾病的临床疗效及安全性观察[J].天津中医药,2017,34(3):163-164,2.
